posted
This PR will make this stock jump today. Closed at $4.41 yesterday.
Vical Receives Broad U.S. Patent for Vaxfectin(R)-Formulated DNA Vaccines for Influenza; Coverage Includes All Seasonal and Pandemic Strains SAN DIEGO, Sept. 3, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of U.S. Patent No. 7,582,613 covering Vaxfectin(R)-formulated DNA vaccines for influenza. The patent provides broad coverage for any circulating or potential influenza viruses, including both seasonal and pandemic strains.
The company is currently developing Vaxfectin(R)-formulated DNA vaccines for both H5N1 avian-origin and H1N1 swine-origin pandemic influenza. Both vaccines are formulated with the company's Vaxfectin(R) adjuvant, a novel lipid-based formulation which has demonstrated significant immune-enhancing ability with a broad range of DNA vaccines and up to 30-fold immune-enhancing ability with a conventional seasonal influenza vaccine. Vaxfectin(R)-formulated H5N1 influenza DNA vaccines completed Phase 1 human testing in 2008.
duckhead
posted
t's going right now at 5.00...
oldseven
posted
Hit a high yesterday of $5.43, closed up 12% at $4.94
oldseven
posted
Up slightly , $5.02
jdizz
posted
oldseven good call
previous close $5.06 premarket at $5.42
steady incline for a year now.. with this news it will hit $8 plus
Vical Pandemic Influenza Vaccine Demonstrates Cross-reactivity Against California, Texas and Mexico H1N1 StrainsFont size: A | A | A6:30 AM ET 9/10/09 | GlobeNewswire Vical Incorporated (Nasdaq:VICL) announced today that the company's DNA vaccine against A/H1N1 pandemic influenza (swine flu) has demonstrated robust immune responses in 100% of vaccinated animals against virus strains isolated from recent outbreaks in three distinct geographic locations -- California, Texas and Mexico.
Vical's plasmid DNA vaccine contains the H1 hemagglutinin gene sequence provided by the U.S. Centers for Disease Control and Prevention (CDC) for the swine-origin A/California/04/09 pandemic influenza virus, and after two doses produced immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits using HI assays against the swine-origin A/California/07/09 x-179a, A/Texas/15/09 and A/Mexico/4108/09 influenza viruses. Hemagglutination inhibition (HI) titers were well above the protection threshold of 40, ranging from 320 to 2,560 in mice, and from 640 to 2,560 in rabbits against the California strain. Results against the Texas and Mexico strains were essentially equivalent, ranging from 640 to 2,560 in both mice and rabbits. Vical's vaccine would also be expected to provide similar robust immune responses against other swine-origin A/H1N1 influenza virus subtypes, supporting selection of a single A/H1N1 virus strain as the basis for the vaccine.
"Cross-reactivity is consistent with previous CDC reports that circulating strains of swine-origin A/H1N1 pandemic influenza have remained antigenically homogeneous," said Vijay B. Samant, President and Chief Executive Officer of Vical, "but future viral changes are unpredictable and could be far more substantial. The inherent speed of our DNA vaccine platform both in initial development and manufacturing could be extremely important in addressing the potential shortfalls of conventional vaccine approaches."
Vical has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC), a biomedical research organization within the U.S. Navy, to develop a vaccine against H1N1 influenza.
posted